---
id: 052
title: Linezolid Spectrum and Mechanism
category: antimicrobials
subcategory: oxazolidinones
tags: [linezolid, MRSA, VRE, oxazolidinones, 50S-ribosome]
difficulty: medium
---

## Question

What is linezolid's mechanism of action and spectrum of activity? Use the **"LINE-up RESISTANT Gram+ bugs"** mnemonic.

## Answer

### **"LINE-up RESISTANT Gram+ bugs" Mnemonic:**

**Linezolid lines up resistant Gram-positives:**
- **L**inezolid targets resistant pathogens
- **I**nhibits 50S ribosome (unique site)
- **N**o cross-resistance with other classes
- **E**xcellent VRE and MRSA coverage

**Resistant bugs covered:**
- **M**RSA (methicillin-resistant *S. aureus*)
- **V**RE (vancomycin-resistant enterococci)
- **P**en-resistant *S. pneumoniae*
- **V**ancomycin-resistant *S. aureus* (VRSA)

### **Mechanism of Action:**

- Binds to **23S rRNA** of **50S ribosomal subunit**
- Unique binding site → **no cross-resistance** with other protein synthesis inhibitors
- Prevents formation of **70S initiation complex**
- Blocks protein synthesis at **earliest step** (before elongation begins)
- **Bacteriostatic** (bactericidal for some strep species)

### **Spectrum of Activity:**

| Organism | Activity | Notes |
|----------|----------|-------|
| **MRSA** | Excellent | Alternative to vancomycin |
| **VRE** | Excellent | *E. faecalis*, *E. faecium* (including vanc-R) |
| **VRSA** | Excellent | Rare but covered |
| ***S. pneumoniae*** | Excellent | Including multidrug-resistant strains |
| ***S. pyogenes* (GAS)** | Excellent | Bactericidal effect |
| **Coagulase-negative staph** | Excellent | Including methicillin-resistant |
| **Viridans streptococci** | Good | Including penicillin-resistant |
| **Gram-negatives** | **NO** | No activity |
| **Anaerobes** | Variable | Some activity but not primary indication |

## Key Points

### **FDA-Approved Indications:**
1. **VRE infections** (including bacteremia)
2. **Nosocomial pneumonia** (MRSA, *S. pneumoniae*)
3. **Complicated skin/soft tissue infections** (MRSA, strep)
4. **Community-acquired pneumonia**

### **Off-Label Uses:**
- MRSA osteomyelitis (good bone penetration)
- MRSA meningitis (excellent CSF penetration)
- Endocarditis (salvage therapy)

### **Pharmacokinetics:**

| Parameter | Value | Clinical Implication |
|-----------|-------|---------------------|
| **Bioavailability (PO)** | ~100% | **PO = IV** (use PO when possible) |
| **Protein binding** | 31% | High free drug levels |
| **CNS penetration** | Excellent | Good for CNS infections |
| **Bone penetration** | Good | Useful for osteomyelitis |
| **Half-life** | 5 hours | BID dosing |
| **Metabolism** | Non-CYP (oxidation) | Minimal drug interactions |

### **Dosing:**
- **Standard:** 600 mg PO/IV BID
- **IV = PO** → switch to PO as soon as tolerated

### **Advantages Over Vancomycin:**
1. **100% bioavailability** (PO = IV)
2. **Better lung penetration** (vanc poor lung levels)
3. **No renal toxicity or need for monitoring**
4. **Superior for MRSA pneumonia** (some studies suggest)

## Sources

- [StatPearls NBK539793: Linezolid]
- [AAFP 2002: Linezolid Role in Drug-Resistant Gram+ Infections]
- [Merck Manual: Linezolid and Tedizolid]

## Media

N/A
